Medtronic (NYSE: MDT) delivered its strongest quarterly organic growth in nearly eight years, excluding COVID, and the market noticed. Shares jumped over 1.5% on the report, closing near $92 after touching a 52-week high above $95 intraday. For a stock that has spent much of the last year trading on tariff worries and separation timelines rather than fundamentals, this was the kind of print that could shift the narrative.
Revenue hit $9.8 billion, up 13.7% organically, while adjusted EPS of $1.45 beat guidance by six cents. Every major segment grew, and management didn’t just meet expectations—it raised them for the rest of fiscal 2027.
That may change the story coming out of earnings. Medtronic has long been treated as a slow-growth medtech name, a dividend payer rather than a growth stock. This earnings report argues otherwise, at least for now.
Medtronic Earnings Beat: Is MDT Stock Ready to Break Out?
Cardiovascular revenue grew 19% year-over-year, led by Cardiac Ablation Solutions, which surged 88% globally and 139% in the U.S. That business surpassed $2 billion in trailing twelve-month revenue and gained nine points of U.S. market share. The Affera Sphere-9 catheter drove much of that momentum, with the U.S. installed base up more than 35% sequentially.
Neuroscience and Medical Surgical also contributed. Cardiac Rhythm Management grew 15% globally. Cranial & Spinal Technologies grew 13%, helped by the newly launched Stealth AXiS platform. Medical Surgical grew 10%, with Acute Care & Monitoring up 14% on video laryngoscope strength.
Hugo, Medtronic’s robotic-assisted surgery system, is on track to surpass 50,000 completed global procedures by fiscal year-end. Procedure growth is running at more than twice the market rate. Altaviva, the company’s tibial neuromodulation implant, saw active implanters more than double sequentially. These are the newer platforms management has been asking investors to be patient with. This quarter, patience started paying off.
Medtronic Stock: Strong Earnings Put Growth Back in Focus
Medtronic raised full-year organic revenue growth guidance by 50 basis points, to a range of 7.25% to 7.75%. Adjusted EPS guidance moved up to $5.94–$6.00, implying 7.4% to 8.5% growth for the year. Management still expects operating profit growth of roughly 10%, with operating margin expanding about 50 basis points.
That guidance bump matters more than the headline beat. Companies routinely beat a single quarter’s numbers without changing the full-year picture. Medtronic did both, and it did so while absorbing tariffs, increased M&A activity, and the pending consolidation of its Diabetes business.
MDT Stock Surges as Medtronic Earnings Change the Narrative
Not everything in this report is pure tailwind. An extra selling week contributed approximately $570 million, or 670 basis points, to organic revenue growth this quarter. That’s a one-time boost. Management expects second-quarter organic growth to normalize to roughly 6%, and it flagged that Acute Care & Monitoring’s mid-teens growth rate should cool as the year progresses.
The company is also spending. A $700 million strategic investment in Cornerstone Robotics expands Medtronic’s global surgical robotics footprint, but it comes with foregone interest expense that will weigh on near-term margins. That’s the trade-off of reinvesting in growth platforms while markets reward immediate profitability.
The planned separation of the Diabetes business, expected via a split-off, remains on track for before the fiscal year-end. But management was careful to note that the timing still depends on achieving optimal economics for shareholders. Guidance currently includes Diabetes for the full year; if the separation closes earlier, expect another revision to guidance.
Medtronic Earnings: Strong Growth Could Finally Lift MDT Stock
When I last covered Medtronic in February, the stock had just posted a strong quarter but only reiterated prior guidance. MDT was sitting at its 150-day moving average, with a possible double-top forming near $95–$100. That support didn’t hold. Shares fell sharply through the spring, bottoming near $76 in early May before beginning a slow climb back.
The chart today looks meaningfully different. MDT closed near $92, comfortably above its 50-day simple moving average of roughly $86. That moving average has been sloping upward since June, a sign the recovery trend has staying power rather than representing a short-lived bounce.
The MACD (12, 26, 9) is also constructive. The MACD line sits above its signal line, with both in positive territory, and the histogram has been green for weeks. That’s a healthier setup than the weakening momentum flagged in the February piece. Volume on the earnings gap was elevated, consistent with genuine buying interest rather than a low-conviction pop.
The stock still needs to clear resistance in the $95–$100 zone, the same range where it topped out last time. A close above $100 would put the December 2025 high near $106 back in play. Until then, treat that zone as the level to watch. A rejection there would echo the pattern from earlier this year.
MDT Stock Has Momentum After Medtronic’s Strong Earnings Beat
Medtronic’s fiscal Q1 report was strong by nearly every measure: revenue, margins, EPS, and forward guidance all moved in the right direction. The perception of Medtronic as a low-growth, tariff-burdened medtech name is increasingly at odds with a company posting double-digit organic growth across every segment. The chart has also repaired itself, trading above a rising 50-day moving average with improving momentum, a contrast to the failed support test that defined the February setup.
That doesn’t mean the stock is a straight line higher from here. The extra selling week flatters this quarter’s growth rate. Acute Care & Monitoring growth should decelerate, and the Cornerstone Robotics investment will pressure near-term margins. The Diabetes separation also remains a moving target. But for investors who track the gap between narrative and numbers, this quarter narrowed it considerably. Medtronic still needs to clear that $95–$100 resistance zone to prove the fundamentals story has staying power. Until it does, the setup is improved, but not yet resolved.
